Kuros Biosciences Reports Results for First Half 2021
. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of product sales to CHF 3.6 million, up from CHF 1.3 Mehr



